BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease

Journal of Infection and Public Health

Volumn 9, Issue 3, 2016, Pages 220-226

  Taylor, Raymond ^a   Kotian, Pravin ^a   Warren, Travis ^b   Panchal, Rekha ^b   Bavari, Sina ^b   Julander, Justin ^c   Dobo, Sylvia ^a   Rose, Angela ^a   El Kattan, Yahya ^a   Taubenheim, Brian ^d   Babu, Yarlagadda ^a   Sheridan, William P ^a  

^a BIOCRYST PHARMACEUTICALS INC   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c UTAH STATE UNIVERSITY   (United States)

^d Wilco Consulting LLC   (United States)

Author keywords

BCX4430; Ebola virus disease; Marburg virus disease; MERS CoV; Nucleoside analog; Yellow Fever

Indexed keywords

ANTIVIRUS AGENT; GALIDESIVIR; 2-(4-AMINO-5H-PYRROLO(3,2-D)PYRIMIDIN-7-YL)-5-(HYDROXYMETHYL)PYRROLIDINE-3,4-DIOL; PURINE NUCLEOSIDE;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL CULTURE; CLINICAL RESEARCH; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EC50; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION; NEGLECTED DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RIFT VALLEY FEVER; SURVIVAL RATE; VIRUS LOAD; VIRUS STRAIN; YELLOW FEVER; YELLOW FEVER VIRUS; ANIMAL; DISEASE MODEL; DRUG DEVELOPMENT; DRUG EFFECTS; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; RNA VIRUS; RNA VIRUS INFECTIONS; TREATMENT OUTCOME; TRENDS; VIROLOGY; VIRUS REPLICATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAPERITONEAL; PURINE NUCLEOSIDES; RNA VIRUS INFECTIONS; RNA VIRUSES; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 84963522462     PISSN: 18760341     EISSN: 1876035X     Source Type: Journal    
DOI: 10.1016/j.jiph.2016.04.002     Document Type: Article

References (7)

1. Elion G.B. Nobel lecture in physiology or medicine - 1988. The purine path to chemotherapy. In Vitro Cell Dev Biol 1989, 25(4):321-330.
2. Whitley R.J., Alford C.A., Hirsch M.S., Schooley R.T., Luby J.P., Aoki F.Y., et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 1986, 314(3):144-149.
3. Kahn J.O., Lagakos S.W., Richman D.D., Cross A., Pettinelli C., Liou S.H., et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992, 327(9):581-587.
4. Lawitz E., Mangia A., Wyles D., Rodriguez-Torres M., Hassanein T., Gordon S.C., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368(20):1878-1887.
5. Warren T.K., Wells J., Panchal R.G., Stuthman K.S., Garza N.L., Van Tongeren S.A., et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014, 508(7496):402-405.
6. Julander J.G., Bantia S., Taubenheim B.R., Minning D.M., Kotian P., Morrey J.D., et al. BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model. Antimicrob Agents Chemother 2014, 58(11):6607-6614.
7. Bergman K.L. The animal rule and emerging infections: the role of clinical pharmacology in determining an effective dose. Clin Pharmacol Ther 2009, 86(3):328-331.